

Typing of *Pseudomonas aeruginosa* from hospitalized patients: a comparison of susceptibility and biochemical profiles with genotype

A.L. Freitas^{1,2}
and A.L. Barth^{1,3}

¹Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil

²Escola de Farmácia, Universidade Católica de Pelotas, Pelotas, RS, Brasil

³Unidade de Pesquisa Biomédica, Serviço de Patologia Clínica, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brasil

Abstract

Typing techniques are essential for understanding hospital epidemiology, permitting the elucidation of the source of infection and routes of bacterial transmission. Although DNA-based techniques are the “gold standard” for the epidemiological study of *Pseudomonas aeruginosa*, antibiotic profiles and biochemical results are used because they are easy to perform and to interpret and relatively inexpensive. Antibiotypes (susceptibility profiles) and biotypes (biochemical profiles) were compared to genotypes established by DNA restriction enzyme analysis in 81 clinical isolates of *P. aeruginosa* from three hospitals in Porto Alegre, Brazil. The epidemiological relationship among patients was also evaluated. Susceptibility and restriction profiles were discrepant in more than 50% of the cases, and many antibiotypes were observed among isolates from the same genotype. Furthermore, susceptibility profiles did not allow the distinction of isolates from unrelated genotypes. Since a large number of isolates (63%) yielded the same biochemical results, only 10 biotypes were detected, showing that this typing method has a low discriminatory power. On the other hand, DNA restriction enzyme typing allowed us to establish 71 distinct types. Epidemiological data about the relation among *P. aeruginosa* isolates were not conclusive. The results of the present study indicate that the only method that can establish a clonal relation is DNA restriction enzyme typing, whereas the other methods may cause misleading interpretations and are inadequate to guide proper infection control measures.

Key words

- *Pseudomonas aeruginosa*
- Typing
- Genotyping
- Phenotypic markers

Correspondence

A.L. Freitas
Barros Cassal, 666/806
90035-030 Porto Alegre, RS
Brasil
Fax: +51-3316-8310
E-mail: usha@via-rs.net

Received January 10, 2003
Accepted October 14, 2003

Introduction

Despite the advances in hospital care and the introduction of a wide variety of antimicrobial agents, *Pseudomonas aeruginosa* continues to be a common cause of nosoco-

mial infections. Typing techniques are essential to establish a clonal relationship between individual isolates in the hospital setting, to recognize outbreaks, and to elucidate the source of infection (1). Although DNA-based techniques have been successfully

applied to the epidemiological study of *P. aeruginosa* (2-4), these procedures are time consuming and expensive and require specific equipment (5,6). Thus, antibiotic susceptibility and biochemical tests are usually employed routinely by clinical laboratories.

Although susceptibility tests provide profiles that are used in infection control, in most cases these data cannot confirm clusters of nosocomial cross-infection or distinguish unrelated infections (5,7-9), especially when multiresistant strains are analyzed (6,10). However, quantitative analysis of antibiograms by comparing disk zone sizes has been considered useful for nosocomial infection control in a few situations (11).

Biochemical tests in combination with production of pigment and hemolysis allow the determination of distinct biotypes. *P. aeruginosa* displays a uniform response to some biochemical tests which are used for identification purposes. However, the variability of the response to other tests can provide different profiles (biotype) that are useful to distinguish clinical isolates. The carbohydrates used for typing include galactose, mannose, mannitol and rhamnose, with utilization rates of 22 to 81% (12). *P. aeruginosa* metabolizes carbohydrates by the oxidative pathway and requires a special culture medium to be detected. Degradation of carbohydrates is evaluated by the oxidative-fermentative (OF) medium. However, the small production of acid by oxidation can be neutralized by alkali released from the breakdown of peptone, preventing the detection of sugar utilization. Therefore, utilization may be better demonstrated in ammonium salt medium, mainly because of the lack of peptone in the medium (13). Urea hydrolysis, which is positive for 43% of *P. aeruginosa* strains, and hemolysis on blood agar, occurring in about half of the clinical isolates, are other useful biochemical tests (13). Most *P. aeruginosa* strains produce pyocyanin and fluorescein, which gives the

characteristic blue-green color to colonies in agar cultures. Some *P. aeruginosa* strains can produce colonies with distinct color due to other pigments, or even non-pigmented colonies (14).

In the present report, 81 clinical isolates of *P. aeruginosa* from hospitalized patients were evaluated for epidemiological relatedness using two phenotypic methods (antibiotic susceptibility and biochemical patterns), molecular analysis (restriction analysis of DNA followed by pulsed-field gel electrophoresis) and epidemiological information (date and place of isolation). Phenotypic and genotypic data were compared to determine the accuracy of antibiotic profiles and biochemical results were compared to establish a clonal relationship among clinical isolates of *P. aeruginosa*.

Material and Methods

Clinical isolates of *P. aeruginosa* recovered from patients with non-cystic fibrosis admitted to three hospitals in Porto Alegre, Brazil, were analyzed in this study. *P. aeruginosa* was identified on the basis of production of pigment, oxidase, glucose, arginine, and nitrate, and growth on ceftrimide agar (12).

The susceptibility tests were performed by the agar disk diffusion method according to the guidelines of the National Committee for Clinical Laboratory Standards (15). To represent the different classes of antimicrobial agents commonly used for the treatment of *P. aeruginosa* we used amikacin, aztreonam, carbenicillin, ceftazidime, ciprofloxacin, imipenem and ticarcillin-clavulanic acid (BBL-Becton Dickinson Microbiology, Cockeysville, Franklin Lakes, NJ, USA). Differences in the results from susceptibility to resistance and from resistance to susceptibility obtained with at least one of the agents characterized a different antibiotype, represented by a lower case letter. Differences in the results from susceptibility to intermedi-

ate, or the contrary, characterized a subtype, represented by an Arabic number added to the antibiotype letter.

Biotyping was performed by observation of hemolysis after growth for 24 h under transmitted light. Hemolytic isolates were divided into two groups according to observation of α or β hemolysis. Production of pigment was determined in Mueller-Hinton medium incubated for 24 h at 35°C, and pigmented colonies were classified according to their color.

Glucose utilization was first assessed with OF medium (BBL-Becton Dickinson Microbiology) using two tubes, one of them overlaid with paraffin oil. Carbohydrate degradation was performed using one tube containing OF medium and one containing ammonium salt sugar medium supplemented with 1% galactose, mannose, mannitol or rhamnose. The tubes were incubated up to 4 days before a negative result was considered. Urea hydrolysis was performed by the method of Christensen (for a review, see Ref. 12). Each group of identical results for pigment, hemolysis, urea hydrolysis and carbohydrate utilization was considered to be a biotype and coded with a number.

Epidemiological relatedness was estimated by geographic and temporal links among patients from each hospital. Patients were considered to be related when they were treated at the same unit and *P. aeruginosa* was isolated within five days. A relation number (R) was given to each group of related patients.

Restriction enzyme analysis of DNA followed by pulsed-field gel electrophoresis was performed as described previously (16). Briefly, the bacteria were embedded in agarose blocks and digested with the restriction endonuclease *SpeI* (Gibco BRL Life Technologies, Rockville, MD, USA). Electrophoresis was carried out using a CHEF DR II apparatus (Bio-Rad, Richmond, CA, USA) at 14°C, 5.9 V/cm, for 22 h, with a time switch of 5 to 50 s. The lambda ladder (48.5

kb; Sigma, St. Louis, MO, USA) was used as the molecular weight marker. The gels were stained with ethidium bromide and the image was acquired with a Chemilmager 4000 (Tech Corporation, Minneapolis, MN, USA). Restriction fragment profiles were compared visually and the criteria of Tenover et al. (17) were used to establish relationships among the isolates. Restriction enzyme analysis was considered to be the "gold standard" for these comparisons (2,3).

Results

We analyzed 81 clinical isolates obtained from patients admitted to three different hospitals between September 1998 and May 1999. Fifty-four percent of the isolates were obtained from the respiratory tract, 28% from urine, 6.5% from blood, and 11.5% from a variety of other sources (catheters, abdominal secretions, skin).

The susceptibility results allowed us to establish 26 major antibiotypes, 3 of them including subtypes, while unique profiles for the isolate were observed in 18 cases. A total of 23 (28.4%) isolates were susceptible to all agents tested, but only 3 were multiresistant (Table 1). Isolates were considered to be multiresistant when they displayed *in vitro* resistance to all tested agents.

Table 1. Major antibiotypes observed in *Pseudomonas aeruginosa* clinical isolates.

Antibiotype	N	%	AMI	ATM	CAR	CAZ	CIP	IMI	TIC
a	23	28.4	S	S	S	S	S	S	S
b	3	7.7	R	R	R	R	R	R	R
c*	9	11.1	R	S	R	S	R	S	R
d*	9	11.1	S	S	I	S	S	S	S
e*	9	11.1	S	S	R	S	S	S	S
f	3	7.7	S	I	R	S	S	S	R
g	3	7.7	R	S	R	S	R	S	S
h	2	7.7	I	S	R	S	R	S	R
k	2	2.5	R	I	R	S	R	R	R

Number of isolates = 81. AMI = amikacin, ATM = aztreonam, CAR = carbenicillin, CAZ = ceftazidime, CIP = ciprofloxacin, IMI = imipenem, TIC = ticarcillin/clavulanic acid, R = resistant, S = susceptible, I = intermediate.

Asterisks indicate antibiotypes that comprise subtypes.

Production of pigment was observed in 79 of 81 isolates, most of them (82.7%) displaying the characteristic green color. All isolates were hemolytic and most of them demonstrated β hemolysis (91.3%). The results of carbohydrate utilization were the same for both the OF and ammonium salt sugar media, although the time needed to

obtain positive results was not always the same. Most isolates were positive for galactose (99%), and only a small number metabolized rhamnose (1%). The results of these tests provided 10 distinct biotypes. Isolates that used urea, galactose, mannose and manitol and displayed a green pigment and β hemolysis belonged to the more frequent biotype (63% of the cases).

Epidemiological analysis yielded 13 groups that included a variable number of patients. Only 2 of these groups (R8, R12) displayed the same antibiotype (Table 2); however, the same biotype was observed in isolates from patients of 9 groups.

A total of 81 isolates of *P. aeruginosa* were submitted to DNA restriction enzyme molecular typing and 71 different DNA profiles (genotypes) were observed among them. Five genotypes were detected in more than one isolate, and genotype D was observed in 5 isolates (Table 3).

Taking the pulsed-field gel electrophoresis profiles as standard, we observed that the same genotype included several distinct antibiotypes, with the exception of multiresistant isolates from clone B which displayed the same profile in all methods used. Genotype D included five isolates belonging to distinct antibiotypes and biotypes (Table 3). However, this profile was also observed in two other unrelated isolates. It was not possible to detect the relationship between the antibiotype and the biotype of the isolates from this clone (Table 3).

Discussion

DNA restriction enzyme analysis (molecular typing) demonstrated that most *P. aeruginosa* isolates belonged to distinct genotypes, demonstrating again that this method had a higher discriminatory power than the phenotypic methods (antibiotyping and biotyping).

The susceptibility typing classified many isolates as antibiotype "a" (fully susceptible to

Table 2. Characteristics of 81 *Pseudomonas aeruginosa* isolates from patients with an epidemiological relation.

Epidemiological relation	No. of isolates	No. of antibiotypes	No. of biotypes	No. of PFGE patterns
R1	9	7	5	7
R2	4	3	2	4
R3	4	3	1	4
R4	4	4	4	3
R5	3	3	2	3
R6	3	3	1	3
R7	3	3	1	3
R8	3	1	1	3
R9	2	2	1	2
R10	2	2	1	2
R11	2	2	1	2
R12	2	1	1	1
R13	2	2	1	2

Epidemiological relatedness was estimated by geographic and temporal links among patients from each hospital. For details, see Material and Methods. Data are reported as number of distinct profiles observed in the group. PFGE = pulsed-field gel electrophoresis (DNA restriction enzyme typing).

Table 3. Characteristics of *Pseudomonas aeruginosa* with DNA restriction enzyme profiles observed in more than one isolate.

Genotype	Antibiotype	Biotype	Epidemiological relation
A	m	1	no relation
A	p*	1	no relation
B	b	1	R12
B1	b	1	no relation
B1	b	1	R12
C	k	1	no relation
C1	r*	1	no relation
D	s*	6	R1
D	d1	9	R1
D	f1	1	R1
D	t*	7	R4
D	m1	5	R4
E	q*	1	no relation
E	c1	1	no relation

Asterisks indicate that antibiotypes are unique for the isolate.

antibiotics); however, all of them displayed distinct DNA restriction enzyme profiles. In fact, antibiotic type “b” (multiresistant to antibiotics) was the only group that included isolates belonging to the same genotype. This may be due to the difference in the number of isolates classified into these groups, only 3 isolates in antibiotic type “b” and 23 isolates in antibiotic type “a”, and therefore a higher variability of genotypes would be more likely to be found in the latter antibiotic type.

Although isolates with unique susceptibility profiles displayed distinct genotypes, the difference in antibiotic type may not guarantee clonal distinction, as many isolates of the same genotype displayed distinct susceptibility profiles, revealing the inadequacy of antibiotyping for typing purposes, as previously described (1,5,9).

The inadequacy of antibiotic type to confirm a clonal relation among multiresistant isolates has been reported (6,10). However, we found antibiotyping useful since all the multiresistant isolates of this study were included in the same genotype. The low prevalence of multiresistant *P. aeruginosa* observed in our study (2.4%) may be the factor responsible for the clonal identity of the isolates.

The low discriminatory power of susceptibility tests is not surprising since the power of a method is determined by the number of types defined by it and the relative frequencies of these types (18). Although we obtained a satisfactory number of groups (26 major groups), the heterogeneous distribution of the isolates in the groups (28.4% in the same antibiotic type) indicated the low discriminatory power of this method.

According to Kiska and Gilligan (12), the rates of utilization of galactose, mannose, mannitol and rhamnose by *P. aeruginosa* are 81, 79, 68 and 22%, respectively, indicating that these tests may be useful to distinguish among clinical isolates. However, in the present study we observed a more homogeneous utilization of carbohydrates than reported by Kiska and Gilligan (12) and, on

the basis of this result, we classified most *P. aeruginosa* into the same group, a fact indicating the poor discriminatory power of biotyping.

Phenotypic methods have been used to screen isolates which may be further typed by a more discriminatory test (7,11,19,20), but in the present study we found biotype and antibiotic type to be unsatisfactory for screening or typing. The combination of the two methods was also insufficient to establish a distinction among isolates from different genotypes. In fact, failure to obtain good quality data using phenotypic methods has been reported previously, also with respect to isolates from cystic fibrosis patients (1,5,6,9,10,20,21).

The isolation of the same bacteria from patients in the same unit may be of help to detect an outbreak (22). However, data from our study and others (23,24) indicate that epidemiological relation among patients is not adequate to establish cross-transmission or outbreaks since no clonal relation may be observed among *P. aeruginosa* strains from these patients. We also observed that isolates of the same genotype may be obtained from unrelated patients, a fact explained by the environmental contribution as a source of infection (25). Phenotypic methods (serotyping and pyocin typing) and pulsed-field gel electrophoresis can demonstrate the same number of identical strains among isolates from an outbreak, while antibiogram profile differs significantly (26).

Although DNA restriction enzyme typing is the “gold standard” for *P. aeruginosa* typing, because of the time required for determination, epidemiological and phenotypic data, mainly susceptibility profiles, are usually employed to indicate a possible outbreak. However, the present study showed that these data are not acceptable as a presumption of relatedness or distinction among *P. aeruginosa* isolates, confirming that only DNA typing can establish a clonal relation.

References

1. Corona ALN, Miranda MGN, Leanos BM, Portilo LG, Hernandez AC, Anthon JR & Aguilar SB (2001). Epidemiologic study of *Pseudomonas aeruginosa* in critical patients and reservoirs. *Archives of Medical Research*, 32: 238-242.
2. Struelens MJ, Schwan V, Deplano A & Baran D (1993). Genome macro restriction analysis of diversity and variability of *Pseudomonas aeruginosa* strains infecting cystic fibrosis patients. *Journal of Clinical Microbiology*, 31: 2320-2326.
3. Grundmann H, Schneider C, Hartung D, Daschner F & Pitt TL (1995). Discriminatory power of three DNA-based typing techniques for *Pseudomonas aeruginosa*. *Journal of Clinical Microbiology*, 33: 528-534.
4. Speijer H, Savelkoul PH, Bonten MJ, Stobberingh EE & Tjhi HT (1999). Application of different genotyping methods for *Pseudomonas aeruginosa* in a setting of endemicity in an intensive care unit. *Journal of Clinical Microbiology*, 37: 3654-3661.
5. Williams T (1997). Evaluation of antimicrobial sensitivity patterns as markers of *Pseudomonas aeruginosa* cross-infection at cystic fibrosis clinics. *British Journal of Biomedical Science*, 54: 181-185.
6. Rodriguez B, Vasquez E, Sussmann O, Mattar S & Jaramillo CA (2000). Antimicrobial susceptibility and serotyping of *Pseudomonas aeruginosa* strains isolated in Bogota, Colombia. *European Journal of Clinical Microbiology and Infectious Diseases*, 19: 152-154.
7. Bergmans D, Bonten M, van Tiel F, Gaillard C, London N, van der Geest S, Leeuw P & Stobberingh E (1997). Value of phenotyping methods as an initial screening of *Pseudomonas aeruginosa* in epidemiologic studies. *Infection*, 25: 350-354.
8. Traub WH, Scheidhauer R, Leonhard B & Bauer D (1998). Surveillance of *Pseudomonas aeruginosa* in intensive care units: clusters of nosocomial cross-infection and encounter of a multiple-antibiotic resistant strain. *Chemotherapy*, 44: 243-259.
9. Muller MP & Gubina M (2000). Serotype, antimicrobial susceptibility and clone distribution of *Pseudomonas aeruginosa* in a university hospital. *Zentralblatt für Bakteriologie*, 289: 857-867.
10. Mifsud AJ, Watine J, Picard B, Charet JC, Solignac CB & Pitt TL (1997). Epidemiologically related and unrelated strains of *Pseudomonas aeruginosa* serotype O12 cannot be distinguished by phenotypic and genotypic typing. *Journal of Hospital Infection*, 36: 105-116.
11. Giacca M & Monti CB (1987). Multivariate analysis of antibiograms for typing *Pseudomonas aeruginosa*. *European Journal of Clinical Microbiology*, 6: 552-558.
12. Kiska DL & Gilligan PH (1999). *Pseudomonas* and *Burkholderia*. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC & Tenover RH (Editors), *Manual of Clinical Microbiology*. 7th edn. American Society for Microbiology, Washington, DC, USA.
13. Cowan ST (1974). *Manual for the Identification of Medical Bacteria*. 2nd edn. Cambridge University Press, London, UK.
14. Pitt TL (1988). Epidemiological typing of *Pseudomonas aeruginosa*. *European Journal of Clinical Microbiology and Infectious Diseases*, 7: 238-247.
15. NCCLS - National Committee for Clinical Laboratory Standards (1999). *Performance Standards for Antimicrobial Disk Susceptibility Tests*. Wayne, PA, USA.
16. Kaufmann ME (1998). Pulsed-field gel electrophoresis. In: Wodford N & Johnson AP (Editors), *Molecular Bacteriology. Protocols and Clinical Applications*. Humana Press Inc., Totowa, NJ, USA, 33-50.
17. Tenover F, Arbeit R, Goering R, Mickelsen P, Murray B, Persing D & Swaminathan B (1995). Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *Journal of Clinical Microbiology*, 33: 2233-2239.
18. Hunter PR & Gaston MM (1989). Numerical index of the discriminatory ability of typing systems: an application of Simpson's index of diversity. *Journal of Clinical Microbiology*, 26: 2465-2466.
19. Renders N, van Belkum A, Barth A, Goessens W, Mouton J & Verbrugh H (1996). Typing *Pseudomonas aeruginosa* strains from patients with cystic fibrosis: phenotyping versus genotyping. *Clinical Microbiology and Infection*, 1: 261-265.
20. Kinoshita M, Sawabe E & Okamura N (1997). Concept of segmentation in nosocomial epidemiology: epidemiological relation among antimicrobial-resistant isolates of *Pseudomonas aeruginosa*. *Journal of Infection*, 35: 269-276.
21. Silbert S, Barth AL & Sader HS (2001). Heterogeneity of *Pseudomonas aeruginosa* in Brazilian cystic fibrosis patients. *Journal of Clinical Microbiology*, 39: 3976-3981.
22. Bennett JV & Brachman PS (1992). *Hospital Infections*. 3rd edn. Little Brown and Company, Boston, MA, USA.
23. Verweij PE, Bijl D, Melchers WJ, Pauw BE, Meis JF, Hoogkamp JA & Voss A (1997). Pseudo-outbreak of multiresistant *Pseudomonas aeruginosa* in a hematology unit. *Infection Control and Hospital Epidemiology*, 18: 128-131.
24. Slama KB, Boudabous A, Skande G, Cherif A, Chedly F, Boelenst H, Maaskant J, Verbrugh H & Belkum A (2001). Heterogeneity among infecting strains of *P. aeruginosa* in diverse departments of a large Tunisian hospital. *Journal of Hospital Infection*, 47: 325-327.
25. Griffith SJ, Nathan C, Selander RK, Chamberlin W, Gordon S, Kabins S & Weinstein R (1989). The epidemiology of *Pseudomonas aeruginosa* in oncology patients in a general hospital. *Journal of Infectious Diseases*, 160: 1030-1036.
26. Sader HS, Pignatari AC, Leme IL, Burattini MN, Tancredi R, Hollis RJ & Jones RN (1993). Epidemiologic typing of multiply drug-resistant *Pseudomonas aeruginosa* isolated from an outbreak in an intensive care unit. *Diagnostic Microbiology and Infectious Disease*, 17: 13-18.